射波刀治疗早期非小细胞肺癌的疗效与观察

摘要

Objective To discuss the clinical efficacy and toxicity of the early non-small cell lung cancer treated by Cyberknife. Methods Retrospective analysis of 28 patients with early non-small cell lung cancer treated by Cyberknife in our department. A total dose of 28—52 Gy ( median of 42. 2 Gy) was delivered in 3—7 fractions. The median isodose curve was 80﹪ ( 65﹪—87﹪) . Results At a median follow-up of 15 months, the primary tumor local control rate was 96. 4﹪. The one-year disease-free survival rate was 96. 4﹪,and the one-year overall survival rate was 100﹪. Pa-tients with grade Ⅰ—Ⅱ radiation pneumonia were observed in 5 ( 17. 9﹪) , gradeⅠ—Ⅱfatigue in 16 (57. 1﹪), and gradeⅢadverse reactions not observed. Conclusion Cyberknife provide another radical treatment option for patients with early non-small cell lung cancer, which showed higher local control rate and lower adverse reaction.%目的：探讨射波刀在早期非小细胞肺癌治疗中的疗效与安全性。方法回顾性分析海军总医院28例接受射波刀治疗的早期非小细胞肺癌患者(Ⅰ～Ⅱ期),处方剂量为28～52 Gy(中位剂量42.2 Gy),分3～7次给予。等剂量曲线水平为65﹪～87﹪(中位水平为80﹪)。结果疾病控制率96.4﹪,随访5～26个月(中位时间15个月),1年无进展生存率为96.4﹪,总生存率100﹪。发生Ⅰ～Ⅱ级乏力16例(57.1﹪),Ⅰ～Ⅱ级放射性肺炎5例(17.9﹪),无Ⅲ级及以上不良反应。结论射波刀治疗早期非小细胞肺癌局部控制率高、不良反应轻,可作为早期非小细胞肺癌患者的根治手段之一。